Global Non-Alcoholic Steatohepatitis Treatment market share 2024, Forecast To 2033
4 Mar, 2024
The non-alcoholic steatohepatitis treatment market has seen exponential growth, rising from$1.89 billion in 2023 to$2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. This growth is attributed to the increasing prevalence of NASH, growing awareness and diagnosis, the obesity epidemic and lifestyle changes, clinical research, improvements in healthcare infrastructure and access, and support from regulatory bodies and clinical trials. Forecasts suggest continued exponential growth, with the market projected to reach$9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%. Growth in the forecast period is driven by advancements in drug development, increased disease awareness, rising prevalence and risk factors, and a shift towards personalized medicine. Major trends in the forecast period include a patient-centric approach, technological advancements, targeted therapies, regulatory landscape changes, and advancements in research.
Global Non-Alcoholic Steatohepatitis Treatment Market Key Driver
An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. Diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045, according to a report from International Diabetes Federation, a Belgium-based global diabetes community. Furthermore, in March 2023, the number of premature deaths from liver disease witnessed a 3.7% increase, totaling 10,501 in 2021, according to a report published by the Office for Health Improvement and Disparities, a UK government department. Among these fatalities, 5,686 were attributed to alcohol-related liver disease in England, while non-alcoholic fatty liver disease accounted for 320 premature deaths. Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.
Get A Free Sample Of The Global Non-Alcoholic Steatohepatitis Treatment Market ReportGlobal Non-Alcoholic Steatohepatitis Treatment Market Segments
The global non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
By Geography: The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa.
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2023. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Non-Alcoholic Steatohepatitis Treatment Industry Players
AstraZeneca PLC, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation
Get The Full Global Non-Alcoholic Steatohepatitis Treatment Market Report
Non-Alcoholic Steatohepatitis Treatment Market Overview
The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2023 provides data on the global non-alcoholic steatohepatitis treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The non-alcoholic steatohepatitis treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.